A Systematical Review on ART Use in HTLV Infection: Clinical, Virological, and Immunological Outcomes
Pathogens · 2024
DOI: 10.3390/pathogens13090721 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pathogens, 2024. Verfasst von Tatiana Fernandez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Pesquisa em Infectologia (LAPI), Hospital Universitário Professor Edgard Santos, Federal University of Bahia, Salvador 40110-060, Braz…. Hauptthemen laut MEDLINE: HTLV-I Infections, Human T-lymphotropic virus 1, Viral Load. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brazilian National Research Council (CNPq), Coordination for the Improvement of Higher Education Personnel scholarship (CAPES).
Abstract (Originalsprache)
Human T-cell lymphotropic virus (HTLV) infection affects over ten million people worldwide, but there is no effective treatment so far. This review describes the virological, immunological, and clinical outcomes of antiretroviral therapy (ART) in people with HTLV infection. This systematic review followed PRISMA reporting guidelines and was registered in PROSPERO: CRD42022350076. The Newcastle–Ottawa Scale, adapted for cross-sectional studies, and Rob-2 were used to assess the methodological quality of these studies. Systematic searches were conducted in the Medline (PubMed), Scopus (Elsevier), Cochrane Library, and Web of Science (Clarivate Analytics) databases. We retrieved data from eight methodologically diverse articles on treatment of patients infected by HTLV-1 or HTLV-2 alone, or coinfected by HIV-1, who received Raltegravir, Tenofovir, Lamivudine, or Zidovudine. The proviral load decreased in three out of seven studies over 4 to 48 weeks of antiretroviral use. Cellular immune response (CD4, CD8, CD25, CD69, and CD71 cells) was evaluated in six studies. While no significant clinical improvement was observed, all studies reported clinical stability during treatment. Despite the demonstrated antiviral activity of ART, in vitro, clinical improvement was not proven. Most studies showed disease stability during ART use, suggesting potential clinical benefits. There is a need of larger, well-controlled trials to define the role of ART in the treatment of HTLV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratório de Pesquisa em Infectologia (LAPI), Hospital Universitário Professor Edgard Santos, Federal University of Bahia, Salvador 40110-060, Brazil.
- Programa de Pós Graduação em Medicina e Saúde (PPgMS), Federal University of Bahia, Salvador 40110-060, Brazil.
ORCID-Profile: Cleyde Marconi, Iris Montaño-Castellón, Felice Deminco, Carlos Brites
Förderung
- Brazilian National Research Council (CNPq)
- Coordination for the Improvement of Higher Education Personnel scholarship (CAPES)
Zitieren
APA
Fernandez, T., Marconi, C., Montaño-Castellón, I., Deminco, F., & Brites, C. (2024). A Systematical Review on ART Use in HTLV Infection: Clinical, Virological, and Immunological Outcomes. Pathogens. https://doi.org/10.3390/pathogens13090721
Vancouver
Fernandez T, Marconi C, Montaño-Castellón I, Deminco F, Brites C. A Systematical Review on ART Use in HTLV Infection: Clinical, Virological, and Immunological Outcomes. Pathogens. 2024. doi:10.3390/pathogens13090721
BibTeX
@article{Fernandez2024,
author = {Fernandez, Tatiana and Marconi, Cleyde and Montaño-Castellón, Iris and Deminco, Felice and Brites, Carlos},
title = {A Systematical Review on ART Use in HTLV Infection: Clinical, Virological, and Immunological Outcomes},
journal = {Pathogens},
year = {2024},
doi = {10.3390/pathogens13090721}
}
EUVIMED